reports
Valneva Submits Label Extension Application for its Chikungunya Vaccin...
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the U.S. Food and Drug Administration (FDA) to potentially extend the use of its chikungunya vaccine IXCHIQ®, which is currently approved in adults, to adolescents aged 12 to 17 years. The application also includes adding the two-year anti...
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Cha...
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and , a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate shigellosis vacc...
Bank of Shanghai Chooses Linedata's Global Hedge Solution to Improve R...
HONG KONG & PARIS--(BUSINESS WIRE)-- (Euronext Paris: LIN), a global provider of asset management and credit technology, data, and services, today announces the successful implementation of its Linedata Global Hedge solution for the (BOSCI). The solution was selected to drive efficiency, value, and enhanced service, especially to improve portfolio management and calculations. BOSCI decided to switch to Linedata Global Hedge to balance cost and value. The transition was completed in Q1 of this year. The senior management from BOSC International Company Limited, a local Chinese investment ba...
Valneva fera des présentations et rencontrera les investisseurs lors d...
Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe Saint-Herblain (France), le 12 novembre 2024 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et participeront à des rendez-vous avec des investisseurs institutionnels lors de prochaines conférences aux États-Unis et en Europe. Lors de ces présentations, Thomas Lingelbach, directeur général, et Peter Bühler, directeur financier, feront un point sur les principaux é...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and Eur...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Saint-Herblain (France), November 12, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming cataly...
- Emira Sagaama
- Juan Ros-Padilla
AMS AMS AG
CRI CHARGEURS SA
EVT EVOTEC SE
FLY SOCIETE FONCIERE LYONNAISE SA
LXS LANXESS AG
BEN BENETEAU SA
KCO KLOECKNER & CO SE
VLS VALNEVA SE
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
GN GN STORE NORD A/S
GLB GLANBIA PLC
DEZ DEUTZ AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
CPINV CARE PROPERTY INVEST SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
DIC DIC ASSET AG
ALFEN ALFEN NV
INS INSTONE REAL ESTATE GROUP AG
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
RWI RENEWI PLC
HGEA HGEARS AG
AF AIR FRANCE - KLM
- Emira Sagaama
- Juan Ros-Padilla
AMS AMS AG
CRI CHARGEURS SA
EVT EVOTEC SE
FLY SOCIETE FONCIERE LYONNAISE SA
LXS LANXESS AG
BEN BENETEAU SA
KCO KLOECKNER & CO SE
VLS VALNEVA SE
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
GN GN STORE NORD A/S
GLB GLANBIA PLC
DEZ DEUTZ AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
CPINV CARE PROPERTY INVEST SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
DIC DIC ASSET AG
ALFEN ALFEN NV
INS INSTONE REAL ESTATE GROUP AG
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
RWI RENEWI PLC
HGEA HGEARS AG
AF AIR FRANCE - KLM
- Damien Choplain
- Martial Descoutures
Valneva : Ixchiq struggling – full-year guidance adjusted
>Top line in line and EBITDA higher than expected – Disappointment on Ixchiq - Valneva reported 9M 2024 results in line with expectation for sales (+0%) and above the css for adjusted EBITDA (+13%). Product sales rose 6% to € 110.4m (+2% vs css) driven by Ixiaro (+31%, +4% vs css) and Dukoral (+6%, +10% vs css) boosted in Q3 (+85%) by the pick-up in marketing outlays. The disappointment in this release came from the performance of Ixchiq which is struggling to get goi...
- Christophe Chaput
- Hela Zarrouk
Beneteau : Lower-than-expected Q3 sales. 2024 guidance confirmed. Redu...
>Q3 sales miss, down 38.6% to € 179.5m (€ 198.7m est) - Bénéteau reported Q3 sales of € 179.5m, 10% below our estimate of € 198.7m and 15% below the consensus (€ 210m). Q3 sales fell 38.6% vs Q3 2023 (after H1 sales were down 31.5%). Dealer destocking in Q3 accounted for -€ 30m (-€ 110m since the beginning of the year) which was consistent with the dealer destocking impact expected for the full year (-€ 100-150m). Over the first nine months of the year, sales came to ...
- Damien Choplain
- Martial Descoutures
Valneva : Ixchiq peine à décoller – guidance FY ajustée
>Topline en ligne et EBITDA au-dessus des attentes – Déception sur Ixchiq - Valneva publie des résultats 9M 2024 en ligne au niveau du CA (+0%) et au-dessus du css au niveau de l’EBITDA ajusté (+13%). Les ventes de produits sont en hausse de 6% à 110.4 M€ (+2% vs Css) tirées par Ixiaro (+31%, +4% vs css) et Dukoral (+6%, +10% vs css) bénéficiant au T3 (+85%) de la reprise des investissements en marketing. La déception de cette publication provient de la performance d’...
- Bruno Bulic
- Oscar Haffen Lamm
Valneva: a mixed-bag of 9M24 results
Valneva has reported a mixed-bag of 9M results with sales at EUR112.5m (cons. EUR110.4m) +12% yoy (excluding Covid-19 revenue in 2023), operating profit of EUR34.2m (cons. EUR29m), translating into an underlying est. EUR61m operating loss excluding the EUR95m profit from the sale of the Priority Vo
- Christophe Chaput
- Hela Zarrouk
Bénéteau : CA T3 < aux attentes. Objectifs 2024 confirmés. Visibilité ...
>Un CA T3 inférieur aux attentes, en baisse de 38.6% à 179.5 M€ (198.7 M€e) - Au titre de son T3, le groupe Bénéteau publie un CA à 179.5 M€, inférieur à nos attentes puisque nous retenions 198.7 M€ (écart -10%) et également de celles du consensus (210 M€ ; écart -15%). Par rapport à l’année dernière, le CA T3 recule de 38.6% (après une baisse de -31.5% sur le S1). Sur le seul T3, le groupe subit un impact d’environ -30 M€ (-110 M€ depuis le début de l’année) lié à la...
Valneva Reports Nine-Month 2024 Financial Results and Provides Corpora...
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to the agreed R&D b...
Valneva publie ses résultats financiers pour les neuf premiers mois de...
Valneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2024 et fait un point sur ses activités Principaux éléments financiers pour les neuf premiers mois de l’exercice 2024 Chiffre d’affaires total de 116,6 millions d’euros comprenant des ventes de produits de 112,5 millions d’eurosBénéfice net de 24,7 millions d’euros incluant le produit de la vente du bon de revue prioritaire (PRV)1 Bénéfice opérationnel de 34,2 millions d’euros contre une perte opérationnelle de (57,2) millions d’euros sur les neuf premiers mois de l’exercice 2023 Trésorerie de 156,3 millions ...
VALNEVA - Declaration of shares and voting rights: October 31, 2024
VALNEVA - Declaration of shares and voting rights: October 31, 2024 VALNEVA Declaration of shares and voting rights October 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: November 6, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal num...
BioSenic provides third quarter 2024 Business Update
BioSenic provides third quarter 2024 Business Update BioSenic provides third quarter 2024 Business Update BioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024, 7.00 am CEST – Regulated Information - (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, today provides its business update for the third quarter, ended 30 September 2024. Key highlights In July 2024, BioSenic sig...
BioSenic fait le point sur ses activités du troisième trimestre 2024
BioSenic fait le point sur ses activités du troisième trimestre 2024 BioSenic fait le point sur ses activités du troisième trimestre 2024 BioSenic lance activement la recherche d'un ou de plusieurs nouveaux actifs par le biais d'un processus de fusion ou d'acquisition Mont-Saint-Guibert, Belgique, le 28 octobre 2024 à 07h00 CEST – Information Reglementée - Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et inflammatoires sévères, ainsi que la réparation cellulaire, fait aujourd’hui un point sur son activité pou...
Valneva to Present on Chikungunya at Several Leading Scientific Confer...
Valneva to Present on Chikungunya at Several Leading Scientific Conferences Saint-Herblain (France), October 21, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today that members of its senior leadership team will present datasets on the world’s first and only approved chikungunya vaccine, IXCHIQ®, at several leading scientific conferences during the fourth quarter of 2024. At the International Society of Vaccines Annual Congress taking place in Seoul, South Korea, Valneva will present on the two-year antibody persistence and safety data of its single-d...
- Christophe-Raphaël Ganet
ODDO : Midcap healthcare Q3 preview: in relative terms, the sector sho...
>+6.4%e forecast after +7.2% in H1 - All told, for Q3 2024 our France healthcare midcap universe should post growth with a slight decline vs H1, i.e. around +6.4%e (this figure should stand at around +5/5.5% excluding the forex effect). Such a trajectory corresponds to a slight slowdown compared to H1 (+7.2% in reported data) and remains slightly higher on an annualised basis (+5.7%e).As a reminder, over 7 years, our sector has performed well and somewhat evenly ...
- Maissa Keskes
- Stephane Houri
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/17/2024
We measured the impact of the contribution from Michel Barnier’s exceptional tax on 88 stocks exposed to France. Some 17 of them would experience a (negative) impact on their EPS of more than 4% on average over 2024 and 2025: LDC (-8.3%), Synergie (-8%), Eiffage (-7.9%), ADP (-7.9%), Dassault Aviation (-7%), Crit (-6.9%), Derichebourg (-6.3%), Hermès (-5.6%), Safran (-5.6%), Bouygues (-5.6%), M6 (-5.2%), Thales (-5%), TF1 (-4.9%), Nexans (-4.9%), Vinci (-4.7%), Compagnie des Alpes (...
FP TOTAL SE
PUB PUBLICIS GROUPE SA
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
MC LVMH MOET HENNESSY LOUIS VUITTON SE
KPN ROYAL KPN NV
RI PERNOD RICARD SA
GFC GECINA SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
WTB WHITBREAD PLC
ABB ABB LTD.
KORI KORIAN SA
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
EL ESSILORLUXOTTICA SA
NESN NESTLE S.A.
BLC BASTIDE LE CONFORT MEDICAL SA
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
VETO VETOQUINOL SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
KER KERING SA
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
AIR AIRBUS SE
01913 PRADA S.P.A.
REP REPSOL SA
MONC MONCLER SPA
DIM SARTORIUS STEDIM BIOTECH SA
SKF B SKF AB CLASS B
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
VACN VAT GROUP AG
BHP BHP GROUP LTD
BP. BP P.L.C.
BIM BIOMERIEUX SA
INPST INPOST S.A.
SHEL SHELL PLC
EAPI EUROAPI
ORP ORPEA
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.